Patents by Inventor David Kirn

David Kirn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
    Publication number: 20210322578
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
    Type: Application
    Filed: March 12, 2021
    Publication date: October 21, 2021
    Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David Kirn
  • Methods and compositions for production of vaccina virus
    Patent number: 10767166
    Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: September 8, 2020
    Assignee: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell
  • ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
    Publication number: 20200009269
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
    Type: Application
    Filed: September 20, 2019
    Publication date: January 9, 2020
    Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David Kirn
  • Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
    Patent number: 10434169
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: October 8, 2019
    Assignees: SILLAJEN, INC, SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • METHODS AND COMPOSITIONS FOR PRODUCTION OF VACCINA VIRUS
    Publication number: 20190169578
    Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David KIRN, John BELL
  • Methods and compositions for production of vaccinia virus
    Patent number: 10202581
    Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: February 12, 2019
    Assignee: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell
  • ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
    Publication number: 20180256751
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
    Type: Application
    Filed: February 8, 2018
    Publication date: September 13, 2018
    Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David KIRN
  • GENERATION OF ANTIBODIES TO TUMOR ANTIGENS AND GENERATION OF TUMOR SPECIFIC COMPLEMENT DEPENDENT CYTOTOXICITY BY ADMINISTRATION OF ONCOLYTIC VACCINIA VIRUS
    Publication number: 20180214538
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 2, 2018
    Applicants: SILLAJEN BIOTHERAPEUTICS, INC., SILLAJEN, INC.
    Inventors: David KIRN, John BELL, Caroline BREITBACH, Anne MOON, Tae-Ho HWANG, Yu Kyoung LEE, Mi-kyung KIM
  • Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
    Patent number: 9919047
    Abstract: The present invention relates to methods and compositions for use in inducing tumor-specific antibody mediated complement-dependent cytotoxic response in an animal having a tumor comprising administering to said animal a composition comprising a replication competent oncolytic virus wherein administration of the composition induces in the animal production of antibodies that mediate a CDC response specific to said tumor.
    Type: Grant
    Filed: January 4, 2012
    Date of Patent: March 20, 2018
    Assignees: SILLAJEN, INC., SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell, Caroline Breitbach, Anne Moon, Tae-Ho Hwang, Yu Kyoung Lee, Mi-kyung Kim
  • Oncolytic vaccinia virus cancer therapy
    Patent number: 9919062
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: March 20, 2018
    Assignee: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David Kirn
  • Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
    Patent number: 9827278
    Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: November 28, 2017
    Assignee: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David Kirn
  • METHODS AND COMPOSITIONS FOR PRODUCTION OF VACCINA VIRUS
    Publication number: 20170298324
    Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.
    Type: Application
    Filed: June 27, 2017
    Publication date: October 19, 2017
    Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David KIRN, John BELL
  • Methods and compositions for production of vaccinia virus
    Patent number: 9719105
    Abstract: Certain embodiments are directed to viral production processes for the large scale production of vaccinia virus.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: August 1, 2017
    Assignee: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventors: David Kirn, John Bell
  • ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
    Publication number: 20160129135
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
    Type: Application
    Filed: December 11, 2015
    Publication date: May 12, 2016
    Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David Kirn
  • Systemic Treatment of Metastatic and/or Systemically-Disseminated Cancers Using GM-CSF-Expressing Poxviruses
    Publication number: 20160038548
    Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.
    Type: Application
    Filed: October 6, 2015
    Publication date: February 11, 2016
    Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: DAVID KIRN
  • Oncolytic vaccinia virus cancer therapy
    Patent number: 9226977
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: January 5, 2016
    Assignee: SillaJen Biotherapeutics, Inc.
    Inventor: David Kirn
  • Oncolytic vaccinia virus combination cancer therapy
    Patent number: 9180151
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected.
    Type: Grant
    Filed: May 8, 2014
    Date of Patent: November 10, 2015
    Assignee: SillaJen Biotherapeutics, Inc.
    Inventors: David Kirn, Caroline Breitbach
  • Systemic treatment of metastatic and/or systemically-disseminated cancers using GM-CSF-expressing poxviruses
    Patent number: 9180149
    Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.
    Type: Grant
    Filed: September 7, 2006
    Date of Patent: November 10, 2015
    Assignee: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David Kirn
  • ONCOLYTIC VACCINIA VIRUS CANCER THERAPY
    Publication number: 20150202325
    Abstract: Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include administering the vaccinia virus at increased viral concentrations. Further aspects of the invention include methods for inducing oncolysis or collapse of tumor vasculature in a subject having a tumor comprising administering to a subject at least 1×108 infectious viral particles of a TK-deficient, GM-CSF-expressing, replication-competent vaccinia virus vector sufficient to induce oncolysis of cells in the tumor.
    Type: Application
    Filed: March 12, 2015
    Publication date: July 23, 2015
    Applicant: SILLAJEN BIOTHERAPEUTICS, INC.
    Inventor: David Kirn
  • Methods and compositions concerning poxviruses and cancer
    Patent number: 8986674
    Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using altered poxviruses, including a vaccinia virus that has been altered to generate a more effective therapeutic agent. Such poxviruses are engineered to be attenuated or weakened in their ability to affect normal cells. In some embodiments, methods and compositions involve poxviruses that possess mutations that result in poxviruses with diminished or eliminated capability to implement an antiviral response in a host. Poxviruses with these mutations in combination with other mutations can be employed for more effective treatment of cancer.
    Type: Grant
    Filed: November 13, 2012
    Date of Patent: March 24, 2015
    Assignee: Sillajen Biotherapeutics, Inc.
    Inventors: David Kirn, Steve H. Thorne